Page last updated: 2024-11-13
buphedrone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
buphedrone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 53249194 |
| CHEMBL ID | 3298875 |
| MeSH ID | M0573994 |
Synonyms (18)
| Synonym |
|---|
| chembl3298875 , |
| bdbm50023180 |
| AKOS015950992 |
| unii-vd73947m0o |
| vd73947m0o , |
| mabp |
| alpha-methylamino-butyrophenone |
| buphedrone |
| 2-(methylamino)-1-phenylbutan-1-one |
| 408332-79-6 |
| J2.929.921H , |
| DDPMGIMJSRUULN-UHFFFAOYSA-N |
| .alpha.-methylamino-butyrophenone |
| 2-(methylamino)-1-phenyl-1-butanone |
| 1-butanone, 2-(methylamino)-1-phenyl- |
| alpha-methylaminobutyrophenone |
| Q4998026 |
| DTXSID701014170 |
Research Excerpts
Overview
Buphedrone is a stimulant that is snorted, smoked or taken orally.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Buphedrone is a stimulant that is snorted, smoked or taken orally." | ( Detection of buphedrone in biological and non-biological material--two case reports. Adamowicz, P; Byrska, B; Zuba, D, 2013) | 1.48 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with buphedrone supported CPP and self-administration, enhanced locomotor activity and produced behavioral sensitization when mice were challenged with methamphetamine." | ( The new designer drug buphedrone produces rewarding properties via dopamine D1 receptor activation. Hong, SI; Hwang, JY; Jang, CG; Kim, HC; Lee, SY; Ma, SX; Oh, JH; Seo, JY, 2018) | 1.14 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (9)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1224714 | Inhibition of NET-mediated norepinephrine uptake in rat synaptosomes | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224718 | Agonist activity at human 5HT2C expressed in HEK293 cells at 10 uM by calcium mobilization assay | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224711 | Induction of DAT-mediated dopamine release in rat synaptosomes | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224712 | Inhibition of SERT-mediated serotonin uptake in rat synaptosomes | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224717 | Agonist activity at human 5HT2B expressed in HEK293 cells at 10 uM by calcium mobilization assay | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224720 | Agonist activity at human 5HT2A expressed in CHOK1 cells at 10 uM after 3 hrs by beta-arrestin recruitment assay | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224715 | Induction of NET-mediated norepinephrine release in rat synaptosomes | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224716 | Agonist activity at human 5HT2A expressed in HEK293 cells at 10 uM by calcium mobilization assay | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| AID1224719 | Agonist activity at human 5HT1A expressed in CHO cells coexpressing Galpha16 at 10 uM by calcium mobilization assay | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 34.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.84) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (12.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||